Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis

Inclusion Criteria: * Age 18 and \< 90 years old * Receiving stable out-subject hemodialysis for a minimum of 3 months * Have a lower arm or upper arm AVF that has been cleared for use by the vascular surgeon or interventional nephrologist * Have agreed to participate voluntarily and signed and dated an IRB approved, subject informed consent form * Dysfunctional Dialysis Fistula: Any subject with * Two or more venous pressure readings exceeding 250 mmHg for a minimum of 5 minutes at a blood flow of 500mls/min within a single dialysis run AND a documented reduction in KT/V by \> 0.2; OR * Patients with venous pressures \> 250 mm Hg on two or more days within a 30 day period OR * Patients who on physical exam are found to have palpable obstructions, post-stenotic dilation of the access or evidence of prolonged post-dialysis bleeding. * Any patient with one of the above conditions will be to have a dysfunctional AVF. This definition will be applied to the screening of study subjects as well as the determination of recurrent fistula dysfunction at 12 months. Exclusion Criteria: * Scheduled for surgical revision of the fistula; * Have been in another investigational (non-approved) drug or device study within the previous 30 days; \*\*have a known allergy to any component of the investigational product (drug or device) * Subjects with a "Hero Graft" will be excluded from the study * Subjects having received a stent for correction of a prior stenosis will be excluded from the trial * Subjects with more than \> 3 hemodynamically significant stenosis at one time (with the exception of a central venous stenosis) * Subjects who are pregnant will be excluded from the trial (pregnancy test will be performed on subjects of child bearing potential). A urine pregnancy test will be utilized.